2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
about
Coming of age: the artificial pancreas for type 1 diabetesA Review of Safety and Design Requirements of the Artificial Pancreas.Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects.Continuous Glucose Monitoring: A Review of Successes, Challenges, and OpportunitiesFuture of Automated Insulin Delivery Systems.In silico assessment of biomedical products: The conundrum of rare but not so rare events in two case studies.Parental evaluation of a telemonitoring service for children with Type 1 Diabetes.Metrics for glycaemic control - from HbA1c to continuous glucose monitoring.Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus ReportThe Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes.Multinational Home Use of Closed-Loop Control Is Safe and Effective.AP@home: The Artificial Pancreas Is Now at HomeStepwise Approach to Problematic Hypoglycemia in Korea: Educational, Technological, and Transplant InterventionsThe tidal waves of connected health devices with healthcare applications: consequences on privacy and care management in European healthcare systems.Closed-loop for type 1 diabetes - an introduction and appraisal for the generalist.Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas.Artificial Pancreas Device Systems for the Closed-Loop Control of Type 1 Diabetes: What Systems Are in Development?Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions.A Novel Insulin/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy.Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home.Remote Blood Glucose Monitoring in mHealth Scenarios: A ReviewPsychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2-month randomized crossover trial.Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.Multivariable Adaptive Artificial Pancreas System in Type 1 Diabetes.Finding the right route for insulin delivery - an overview of implantable pump therapy.Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use.Glucose Control in the ICU: A Continuing Story.Enhanced Model Predictive Control (eMPC) Strategy for Automated Glucose Control.A Review of the Current Challenges Associated with the Development of an Artificial Pancreas by a Double Subcutaneous Approach.The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes.Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel sGlycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial.Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.12-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia.Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial.Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial.Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes.Bridging technology and clinical practice: innovating inpatient hyperglycaemia management in non-critical care settings.Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial.Manual Closed-Loop Insulin Delivery Using a Saddle Point Model Predictive Control Algorithm: Results of a Crossover Randomized Overnight Study.
P2860
Q26745886-8B1E94F2-FFC1-40F6-8841-B0EB08557C46Q28066687-19E343AD-1462-49A5-A10F-50FC675B5212Q28071439-C42CB83D-09B2-4341-9230-D14CB2381EF0Q28076888-1CC7ADCF-607B-481A-A531-BCD0F5180332Q30252197-086EAC1B-74BC-46C5-BA3D-0D6D54673A97Q30252581-F23443FC-EA20-436C-ABDD-E52C3EE0E8A3Q30252858-FF6E0887-B7C9-4B1B-8028-C98CE874CAD8Q30252932-AFB13F09-AC20-49CE-AEF4-DA9CACF3EF5FQ30276532-F90848B0-BEEA-4C79-AF78-8CBE203826A4Q30276534-7F3BA217-EFE0-4CAC-8736-8169A6B73716Q30276768-5B283C33-883C-4B20-AF4C-CE0FF8FE2994Q30354088-63F9BB12-361D-4B28-ACB3-4B639DB5E57FQ33889841-90FD72E1-977F-4475-8D2D-BDAEC6FA4471Q36251889-EBED1554-C89F-4076-B8D0-3B676D28FEA5Q36258001-6F3A9C3F-2DB6-466B-AFE5-4715B20084EFQ37025582-E1D9206A-1CF7-4EA1-9601-4E59B3C4F773Q37288511-641274BD-582C-4412-8769-6C9BD889A73BQ37288539-F145A0A1-8BC4-45BE-A91C-891836DA623EQ37400145-A83E4ABF-F683-4CF2-A83C-C30DDFFFEA3DQ37418102-F0848E14-79BF-486F-8554-D986DC4C3BBBQ37537150-1CC2F571-E134-4AA3-9AF0-465A8A75B6A8Q37596028-8EC41C6F-1EB4-4DBB-9382-02F7F57ADAFDQ37736558-5E5F78E2-1187-4C18-AA2C-263B40C83090Q38622678-013B19BB-4283-4B40-BE97-6741A60BAD76Q38788065-77B6A247-F288-43F8-8F3C-C523286467A8Q38821167-9123B202-960A-4A97-B78D-261F85EC9191Q38832644-8B2C7E01-69DF-40DA-8986-B736DE16FAF3Q39110148-16CA8C87-0961-4071-91D8-E0C6BD479981Q39306224-6E728E24-1E49-47ED-83CD-37A8262520E7Q39413453-AAAE7043-3671-4D5D-B6B4-24AE13652EF5Q39436182-5ECE636E-B770-4F9C-94BB-398DA1FC16E1Q41259339-0C2254B5-B677-4D1D-B6C1-4D7C660017F2Q42660514-11CE36C8-10F8-4FAB-99EC-5A528660AC0BQ42696179-F9E65834-CE44-4DB5-8EE6-10DB7C172CA6Q42718199-815ED644-B78E-40D7-9C3A-D55AEA040B33Q44372769-EBF8A3D7-45CF-419C-B56F-272CBEDBA2D0Q45062397-49CC72E3-FB55-4424-9697-F766E6613D7CQ47269489-1A50A449-AED1-42F6-A69C-8C7D08930161Q47288459-937BE2EC-20F3-4FBF-BE2D-A4F930B32C95Q47778034-DC371FC7-F4BE-42F9-9D6C-2409E0A77D98
P2860
2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
2 month evening and night clos ...... a randomised crossover trial.
@ast
2 month evening and night clos ...... a randomised crossover trial.
@en
type
label
2 month evening and night clos ...... a randomised crossover trial.
@ast
2 month evening and night clos ...... a randomised crossover trial.
@en
prefLabel
2 month evening and night clos ...... a randomised crossover trial.
@ast
2 month evening and night clos ...... a randomised crossover trial.
@en
P2093
P50
P1476
2 month evening and night clos ...... a randomised crossover trial.
@en
P2093
AP@home consortium
Angelo Avogaro
Anne Farret
Boris P Kovatchev
Eric Renard
Federico Boscari
Federico Di Palma
Giordano Lanzola
J Hans DeVries
Jerome Place
P304
P356
10.1016/S2213-8587(15)00335-6
P50
P577
2015-09-29T00:00:00Z